USPTO Examiner CHONG YONG SOO - Art Unit 1627

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18441600TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024June 2024Allow400YesNo
18441611TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024July 2024Allow500YesNo
18441621TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024July 2024Allow500YesNo
18441597TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEFebruary 2024August 2024Allow600YesNo
184889671-(3-CHLOROBENZYLIDENEAMINO)-5,5-DIPHENYLIMIDAZOLIDINE-2,4-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023January 2024Allow300YesNo
18377606HMOX1 INDUCERSOctober 2023April 2024Allow611YesNo
18549374Deuterated EmpathogensSeptember 2023May 2024Allow811YesNo
18260853QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USESJuly 2023February 2024Allow701YesNo
18210555PROTEASE INHIBITORS AS ANTIVIRALSJune 2023January 2024Allow701YesNo
18210526METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINJune 2023August 2023Allow200YesNo
18208017COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USEJune 2023February 2024Allow910YesNo
18137094EXTRACTION OF ABSCISIC FROM STRAWBERRIESApril 2023May 2024Abandon1221NoNo
18299701TREATMENT OF SEIZURE DISORDERSApril 2023May 2024Allow1340YesYes
18099279PANTOTHENAMIDE ANALOGUESJanuary 2023July 2023Allow601YesNo
18095199TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEJanuary 2023November 2023Allow1031YesNo
18095205TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEJanuary 2023November 2023Allow1030YesNo
18095202TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEJanuary 2023November 2023Allow1030YesNo
18083824COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USEDecember 2022March 2023Allow200YesNo
18077876METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINDecember 2022March 2023Allow300YesNo
17256848DERIVATIZED BENZIMIDAZOLE COMPOUNDS, THEIR SALTS, THEIR COMPLEXES, THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USING THEM FOR ANTIGERIATRIC ACTIONSNovember 2022September 2023Allow3311YesNo
17975127ENANTIOMERIC RATIOS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE AND RELATED METABOLITES AND USES THEREOFOctober 2022March 2024Abandon1621YesNo
17953819Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain CancerSeptember 2022April 2024Allow1910NoNo
17953867Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain CancerSeptember 2022April 2024Allow1910NoNo
17946508NITRILATED PSILOCYBIN DERIVATIVES AND METHODS OF USINGSeptember 2022December 2023Allow1521YesNo
17940950Methods of Treating Psychological and Brain DisordersSeptember 2022April 2024Abandon2021NoNo
17823489TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITEAugust 2022November 2023Allow1531YesNo
17896774METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)August 2022June 2024Allow2211YesNo
17820183PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAMEAugust 2022December 2023Allow1610YesNo
17818836METABOLISM ENHANCING COMPOSITIONSAugust 2022October 2023Allow1501YesNo
17883210MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERSAugust 2022December 2023Allow1701NoNo
17868106METHODS OF TREATING RESPIRATORY DISORDERSJuly 2022April 2024Abandon2101NoNo
17847860GAMMA-HYDROXYBUTYRATE SALTS FOR THE TREATMENT OF PSYCHOLOGICAL DISORDERSJune 2022October 2023Allow1601YesNo
17834390GAMMA-HYDROXYBUTYRATE SALTS FOR THE TREATMENT OF LEARNING DISORDERSJune 2022September 2023Allow1501YesNo
17805643METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUSJune 2022August 2023Allow1420YesYes
17748098METHODS OF TREATMENT OF PARTIAL ONSET SEIZURES USING ESLICARBAZEPINE ACETATEMay 2022April 2024Abandon2310YesNo
17746625METHODS OF TREATING HYPERTRIGLYCERIDEMIAMay 2022May 2024Abandon2410NoNo
17745823SUBLINGUAL OR BUCCAL ADMINISTRATION OF DIM FOR TREATMENT OF SKIN DISEASESMay 2022October 2024Abandon2910NoNo
17743653CANNABIDIOL-TYPE CANNABINOID COMPOUNDMay 2022October 2022Allow501YesNo
17741146PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND AN AURORA KINASE INHIBITOR AND METHODS OF USE THEREOFMay 2022August 2023Allow1600YesNo
17661116NOVEL LEVOTHYROXINE FORMULATIONS FOR ORAL USEApril 2022August 2023Allow1600YesNo
17660479METHODS AND COMPOSITIONS FOR IMPROVING SLEEPApril 2022August 2023Allow1600YesNo
17718819METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)April 2022June 2022Allow200YesNo
17707542COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USEMarch 2022November 2022Allow811YesNo
17655646SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPYMarch 2022October 2023Allow1901YesNo
17691448TREATMENT OF ADHDMarch 2022April 2024Abandon2511NoNo
17652642COMPOSITIONS COMPRISING PROTOCATECHUIC ACID AND METHODS OF USEFebruary 2022September 2024Abandon3041NoYes
17651879TREATMENT OF NF-KB-MEDIATED DISEASEFebruary 2022January 2024Abandon2330NoNo
17586657AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTSJanuary 2022June 2023Allow1730NoNo
17573979HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDESJanuary 2022February 2024Allow2511YesNo
17568560Compositions and Methods for Treating Metabolic DisordersJanuary 2022March 2024Abandon2601NoNo
17560035AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTSDecember 2021October 2022Allow1011NoNo
17540962METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBINDecember 2021September 2022Allow910YesNo
17456617NOVEL COMBINATIONS OF A H3 ANTAGONIST AND A NORADRENALINE REUPTAKE INHIBITOR, AND THE THERAPEUTICAL USES THEREOFNovember 2021December 2023Allow2401YesNo
17532646THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOFNovember 2021June 2022Allow601YesNo
17533061METHODS AND COMPOSITIONS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASENovember 2021March 2024Abandon2731YesNo
17527440Compositions Comprising Oxo-Derivatives of Fatty Acids and Methods of Making and Using SameNovember 2021February 2024Allow2701YesNo
17526816REAGENTS AND METHODS FOR ESTERIFICATIONNovember 2021June 2024Allow3111YesNo
17453432METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF CONDITIONS CAUSED BY AN ENVELOPED VIRUSNovember 2021June 2024Allow3241YesYes
17501692Compositions and Methods for Treating Patients Suffering from Glioma or LeukemiaOctober 2021September 2023Allow2310YesNo
17496532ANTAGONISTS OF CB1 RECEPTOROctober 2021January 2024Abandon2801NoNo
17488966DIROFILARIA VOLATILE ORGANIC COMPOUND SIGNATURES AND USES THEREOFSeptember 2021August 2022Allow1101YesNo
17489244COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUSSeptember 2021April 2024Allow3110NoNo
17477444COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERSSeptember 2021December 2022Allow1521YesNo
17477415COMPOSITIONS AND METHODS FOR TREATING NEUROPSYCHIATRIC DISORDERSSeptember 2021August 2022Allow1121YesNo
17470436COMPOSITIONS AND TREATMENTS FOR MICROBIAL PERSISTER CELLSSeptember 2021May 2024Abandon3371YesNo
17458976Methods and Compositions for Pest ControlAugust 2021October 2023Abandon2610NoNo
17407689USE OF HOMOHARRINGTONINE IN PREPARATION OF BETACORONAVIRUS REPLICATION INHIBITOR IN HUMANAugust 2021August 2023Allow2441YesNo
17377898CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHODJuly 2021May 2024Abandon3411NoNo
17373284USE AND METHOD OF L-ASPARTIC ACID beta-HYDROXAMATE IN PREPARING DRUGS FOR INHIBITING CHOROIDAL NEOVASCULARIZATIONJuly 2021March 2023Allow2000YesNo
17372272Inhibition of Acetyl-CoA Metabolism for Treatment and Prevention of Immune System Diseases and DisordersJuly 2021November 2023Abandon2801NoNo
17418871PANTOTHENAMIDE ANALOGUESJune 2021September 2022Allow1501YesNo
17419101ANTI-HELICOBACTER FOOD COMPOSITION COMPRISING BETA-CARYOPHYLLENEJune 2021November 2022Abandon1620NoNo
17358471METHODS FOR TREATING NEURODEGENERATIVE DISORDERSJune 2021March 2024Allow3210NoNo
17330182MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN APURINIC/APYRIMIDINIC ENDODEOXYRIBONUCLEASE PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDEMay 2021September 2022Allow1521NoNo
17327465TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAMMay 2021April 2022Abandon1110NoNo
17306458METHODS OF TREATING EOSINOPHILIC ESOPHAGITISMay 2021November 2022Allow1821YesNo
17244337MONOLITHIC TABLETS BASED ON CARBOXYL POLYMERIC COMPLEXES FOR CONTROLLED DRUG RELEASEApril 2021May 2024Abandon3611NoNo
17228590METHODS OF TREATING RBP4 RELATED DISEASES WITH TRIAZOLOPYRIDINESApril 2021December 2023Allow3311NoNo
17275608NEAR-INFRARED NERVE-SPARING BENZO[C]PHENOXAZINE FLUOROPHORESMarch 2021February 2024Allow3500NoNo
17188850Long Term Treatment of HIV-Infection With TMC278March 2021October 2023Abandon3110YesNo
171665607-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZO[1,2-A]PYRIDO[3,4-E]PYRIMIDIN-5 (1H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPYFebruary 2021March 2024Abandon3720NoNo
17264798New use of carbamate � phenylethanolamine analogues for enhancing intracellular clearance of LDL cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effectsJanuary 2021July 2023Abandon3011NoNo
17147867PYRVINIUM PAMOATE THERAPIES AND METHODS OF USEJanuary 2021January 2024Abandon3601NoNo
171122822-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-C]PYRIDINES AND THEIR ANTI-INFLAMMATORY USES THEREOFDecember 2020February 2023Allow2600YesNo
17103455MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTSNovember 2020April 2023Allow2901YesNo
17054686NOVEL MODULATOR OF METABOTROPIC AND IONOTROPIC TRANSMEMBRANE RECEPTORS AND USE THEREOFNovember 2020April 2022Allow1801YesNo
17088063ESTER NITRATES DERIVATIVES OF AROMATIC ALDEHYDES WITH MULTIPLE PHARMALOGIC PROPERTIES TO TREAT SICKLE CELL DISEASENovember 2020January 2024Abandon3810YesNo
17083569INHIBITORS OF INFLUENZA VIRUSES REPLICATIONOctober 2020December 2023Abandon3701NoNo
17076379TREATMENT METHOD FOR CORONAVIRUS INFECTIONOctober 2020November 2023Abandon3730YesNo
17072511USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERSOctober 2020January 2023Allow2700NoNo
17062982DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITOROctober 2020May 2022Allow2000YesNo
17025130USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSYSeptember 2020October 2022Abandon2531YesNo
16981430SOLID FORM OF DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOFSeptember 2020June 2022Allow2101YesNo
17018221ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOFSeptember 2020February 2023Allow2900NoNo
17010153COMPOSITION FOR PROMOTING SKELETAL MUSCLE ACTIVITY VIA INDUCTION OF MITOCHONDRIAL BIOGENESIS COMPRISING OF AZELAIC ACID AS AN ACTIVE INGREDIENTSeptember 2020November 2023Allow3941YesNo
17001127METHODS OF TREATING TESTOSTERONE DEFICIENCYAugust 2020May 2023Abandon3210NoNo
17000301COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASESAugust 2020July 2022Allow2301YesNo
16947759METHODS OF TREATING SARS COV-2 VIRUS WITH PROTOCATECHUIC ACIDAugust 2020February 2021Allow610YesNo
16987609ESTER NITRATES DERIVATIVES OF AROMATIC ALDEHYDES WITH MULTIPLE PHARMALOGIC PROPERTIES TO TREAT SICKLE CELL DISEASEAugust 2020October 2020Allow311NoNo
16943871COMBINATION THERAPY FOR THE TREATMENT OF MASTOCYTOSISJuly 2020May 2024Allow4621NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, YONG SOO.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
55
Examiner Affirmed
29
(52.7%)
Examiner Reversed
26
(47.3%)
Reversal Percentile
68.5%
Higher than average

What This Means

With a 47.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
190
Allowed After Appeal Filing
45
(23.7%)
Not Allowed After Appeal Filing
145
(76.3%)
Filing Benefit Percentile
28.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CHONG, YONG SOO - Prosecution Strategy Guide

Executive Summary

Examiner CHONG, YONG SOO works in Art Unit 1627 and has examined 889 patent applications in our dataset. With an allowance rate of 42.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner CHONG, YONG SOO's allowance rate of 42.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHONG, YONG SOO receive 2.20 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHONG, YONG SOO is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +56.9% benefit to allowance rate for applications examined by CHONG, YONG SOO. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 9.5% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.2% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 76.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 55.6% of appeals filed. This is in the 23% percentile among all examiners. Of these withdrawals, 42.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 43.6% are granted (fully or in part). This grant rate is in the 47% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.1% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.